Ultima-Tesamorelin 2mg

MANUFACTURER Ultima Pharmaceuticals - USA
WAREHOUSE USA Warehouse 5
SUBSTANCE GHRH Peptide

Your privacy and security are paramount; hence, all products are shipped without branding.

Introducing Tesamorelin, a powerful formulation featuring a growth hormone-releasing factor (GRF). This innovative medication is specifically designed to assist individuals dealing with excess abdominal fat associated with certain HIV treatments, commonly known as lipodystrophy.

It's essential to understand that Tesamorelin is not meant for weight loss and should never be used as a treatment for obesity.

Indicated for injection, Tesamorelin targets the reduction of excess abdominal fat in HIV-infected individuals experiencing lipodystrophy.

Restrictions on Use:

• The long-term cardiovascular safety and benefits of Tesamorelin are yet to be fully researched. Therefore, it is vital to evaluate the continuation of treatment in patients who do not show a significant response, as indicated by a decrease in visceral fat measured through waist circumference or CT imaging.
• Tesamorelin is not approved for weight loss and maintains a weight-neutral effect.
• There is no evidence to suggest that Tesamorelin enhances adherence to antiretroviral treatments for HIV-positive patients.

General Dosage Guidelines:

The recommended dosage for Tesamorelin is 2 mg, to be administered subcutaneously once daily. The abdomen is the preferred injection site, and it is advisable to rotate injection locations within different areas of the abdomen. Avoid areas with scar tissue, bruises, or close to the navel.

Reconstitution Instructions:

Tesamorelin should be reconstituted using the provided diluent. To do so, combine the 2 mg vial of Tesamorelin with 2.1 mL of the diluent. Gently roll the vial in your hands for 30 seconds to mix; avoid shaking.

Detailed reconstitution instructions can be found in the INSTRUCTIONS FOR USE leaflet included with the Tesamorelin and diluent packaging.

Administer Tesamorelin immediately after reconstitution and dispose of any unused solution. If not used right away, discard the reconstituted solution. Never freeze or refrigerate the reconstituted Tesamorelin.

Administration:

Before administration, visually inspect the reconstituted Tesamorelin for any particulate matter or discoloration. Only inject if the solution is clear, colorless, and free of particles. Inject Tesamorelin subcutaneously into the abdomen, ensuring to rotate injection sites and avoiding areas with scar tissue, bruises, or near the navel.